Revelation Biosciences REVB

Revelation Biosciences, Inc. is a clinical stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The company is developing Gemini for the treatment of acute kidney injury and chronic kidney disease through its GEM AKI and GEM CKD programs. Revelation Biosciences, Inc. was incorporated in the state of Delaware on November 20 2019 and is headquartered in San Diego California. Its common stock and warrants are listed on the Nasdaq Stock Market under the ticker symbols REVB and REVBW respectively.

As a clinical stage company Revelation Biosciences, Inc. has not yet generated product revenue. Its current financial resources come from public equity offerings and potential future licensing or collaboration agreements. The company expects to generate revenue upon successful development and commercialization of its Gemini based product candidates.

Revelation Biosciences, Inc. operates in the competitive biopharmaceutical sector focusing on immunomodulatory therapies for kidney diseases. Its primary competitors include larger pharmaceutical companies such as those marketing Farxiga for chronic kidney disease and various firms developing acute kidney injury treatments. The company differentiates itself through its Gemini platform which modulates Toll like receptor 4 to rebalance inflammatory responses without broadly suppressing immunity. This mechanism aims to address the underlying inflammation driving both acute and chronic kidney injury a gap not fully covered by existing standard of care.

The company’s potential customers include hospitals dialysis centers and healthcare providers that treat patients with acute kidney injury or chronic kidney disease. While specific customer names are not disclosed in the filing the target market comprises medical institutions and physicians specializing in nephrology and critical care.